Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)

Sylvia Adams, Lori J. Goldstein, Joseph A. Sparano, Sandra Demaria, Sunil S. Badve

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

pon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).1 Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalOncoImmunology
Volume4
Issue number9
DOIs
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • Biomarker
  • Breast cancer
  • TNBC
  • Tumor infiltrating lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this